Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Personalized tissue-engineered arteries as vascular graft transplants: A safety study in sheep
VERIGRAFT AB, Sweden.
Sahlgrenska Academy, Sweden.
RISE Research Institutes of Sweden, Materials and Production, Product Realisation Methodology.
VERIGRAFT AB, Sweden; University of Gothenburg, Sweden; Sahlgrenska University Hospital, Sweden.
Show others and affiliations
2022 (English)In: Regenerative Therapy, ISSN 2352-3204, Vol. 21, p. 331-341Article in journal (Refereed) Published
Abstract [en]

Patients with cardiovascular disease often need replacement or bypass of a diseased blood vessel. With disadvantages of both autologous blood vessels and synthetic grafts, tissue engineering is emerging as a promising alternative of advanced therapy medicinal products for individualized blood vessels. By reconditioning of a decellularized blood vessel with the recipient's own peripheral blood, we have been able to prevent rejection without using immunosuppressants and prime grafts for efficient recellularization in vivo. Recently, decellularized veins reconditioned with autologous peripheral blood were shown to be safe and functional in a porcine in vivo study as a potential alternative for vein grafting. In this study, personalized tissue engineered arteries (P-TEA) were developed using the same methodology and evaluated for safety in a sheep in vivo model of carotid artery transplantation. Five personalized arteries were transplanted to carotid arteries and analyzed for safety and patency as well as with histology after four months in vivo. All grafts were fully patent without any occlusion or stenosis. The tissue was well cellularized with a continuous endothelial cell layer covering the luminal surface, revascularized adventitia with capillaries and no sign of rejection or infection. In summary, the results indicate that P-TEA is safe to use and has potential as clinical grafts. 

Place, publisher, year, edition, pages
Japanese Society of Regenerative Medicine , 2022. Vol. 21, p. 331-341
Keywords [en]
ATMP, Blood vessels, Recellularization, Regenerative medicine, Scaffold, Tissue engineering, amoxicillin, attane, buprenorphine, carprofen, clopidogrel, dalteparin, dexmedetomidine, heparin, isoflurane, norocarp, poliglecaprone, promea, propofol, receptor type tyrosine protein phosphatase C, vetergesic, vetrimoxin, adventitia, anatomical concepts, angiography, animal experiment, animal model, animal tissue, antibiotic prophylaxis, arterial stiffness, artery anastomosis, artery transplantation, Article, biomechanics, biopsy technique, blood flow, blood vessel graft, blood vessel parameters, blood vessel wall, burst pressure, capillary, carotid artery transplantation, confocal laser scanning microscopy, controlled study, decellularization, decellularized blood vessel, device safety, DNA extraction, end to end anastomosis, endothelial cell layer, evening dosage, extracellular matrix, failure strain, female, fluorescence microscopy, full luminal endothelialization, histology, hyperplasia, immunohistochemistry, intimal hyperplasia, luminal surface, medical procedures, morning dosage, nonhuman, reconditioning of vascular graft, revascularization, scanning electron microscopy
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:ri:diva-60256DOI: 10.1016/j.reth.2022.08.005Scopus ID: 2-s2.0-85137671619OAI: oai:DiVA.org:ri-60256DiVA, id: diva2:1702189
Note

Funding details: Horizon 2020 Framework Programme, H2020; Funding details: H2020 Marie Skłodowska-Curie Actions, MSCA, 722779; Funding details: VINNOVA, Dnr 2017-01413, Dnr 2017–02983; Funding text 1: We want to acknowledge the staff at the Department of Experimental Biomedicine at Gothenburg University. This study was partly performed by funding from VINNOVA (Dnr 2017–02983 and Dnr 2017-01413) and Region Västra Götalandsregionen (consultant check) as well as from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 722779 conducted within the “Training 4 Cell Regenerative Medicine” (T4CRM) network. The company VERIGRAFT AB holds a patent on peripheral whole blood perfusion of decellularized tissues and did also finance the project.; Funding text 2: We want to acknowledge the staff at the Department of Experimental Biomedicine at Gothenburg University. This study was partly performed by funding from VINNOVA ( Dnr 2017–02983 and Dnr 2017-01413 ) and Region Västra Götalandsregionen (consultant check) as well as from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 722779 conducted within the “Training 4 Cell Regenerative Medicine” (T4CRM) network. The company VERIGRAFT AB holds a patent on peripheral whole blood perfusion of decellularized tissues and did also finance the project.

Available from: 2022-10-10 Created: 2022-10-10 Last updated: 2023-10-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records

Stenlund, PatrikPetronis, SarunasKrona, AnnikaHåkansson, Joakim

Search in DiVA

By author/editor
Stenlund, PatrikPetronis, SarunasKrona, AnnikaHåkansson, Joakim
By organisation
Product Realisation MethodologyAgriculture and Food
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 63 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf